<DOC>
	<DOCNO>NCT02201823</DOCNO>
	<brief_summary>Ability Pharmaceuticals promote clinical trial determine adequate dose new drug , ABTL0812 , administer orally daily patient advance solid tumor .</brief_summary>
	<brief_title>Phase I/Ib Clinical Trial ABTL0812 Advanced Cancer Patients</brief_title>
	<detailed_description>This phase I/Ib , unicenter , open-label single-agent study . This study consist two different part , dose escalation phase extension phase patient advance solid tumor . ABTL0812 administer orally , daily , 28 day ( consider cycle 1 ) . First endpoint determine Maximum Tolerated Dose ( MTD ) . MTD define high dose one six patient experience ABTL0812 relate Dose-Limiting Toxicity ( DLT ) . DLT evaluate first treatment cycle . Dose escalation phase perform accelerated design 3 + 3 Once 28 day cycle finish , patient may continue receive ABTL0812 daily continuous schedule patient deem clinical benefit treatment , accord treat physician . Treatment continue disease progression , onset unacceptable drug toxicity , patient/physician 's request discontinue .</detailed_description>
	<criteria>Patients older 18 year age Willing able provide inform consent Patients histologically cytologically confirm diagnosis advance solid tumour refractory standard treatment effective therapy exist Evaluable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) Version 1.1 guideline Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 All female subject consider childbearing potential unless postmenopausal ( least 12 month consecutive amenorrhea , appropriate age group without know suspected cause ) , sterilize surgically Female subject childbearing potential must agree use two form highly effective contraception method study period 6 month follow last administration study drug . Male subject female partner childbearing potential practicing total abstinence , must agree use two form highly effective contraception study period 6 month follow last administration study drug Adequate bone marrow function Adequate coagulation profile Adequate hepatic function Adequate renal function Life expectancy least 3 month , opinion investigator Toxicities incur result previous anticancer therapy ( radiation therapy , chemotherapy , surgery ) must resolve ≤ grade 1 ( defined Common Terminology Criteria Adverse Events version 4.02 ) . Ability willingness comply study visit , treatment , test , comply protocol Patients receive treatment within 4 week prior study entry investigational drug , chemotherapy , target agent hormonal therapy ( patient may continue receive Luteinizinghormonereleasing hormone analogue therapy prostate cancer face rise PSA ) , radiation ( except bone ) surgery ( except exploratory biopsy intravenous device implantation , etc . ) ( 6 week nitrosoureas Mitomycin C , investigational drug within 5 halflives treatment , whichever long ) . Participation noninterventional observational study allow . Patients symptomatic brain metastasis . Patients asymptomatic brain metastasis include study keep stable dos steroids period 1 month prior study entry . Patients gastrointestinal abnormality include inability take oral medication , malabsorption syndrome clinically significant gastrointestinal abnormality may impair absorption investigational medicinal product . Pregnancy lactation . Serum pregnancy test perform within 7 day prior study treatment start . Patients myocardial infarction within ≤ 12 month prior study entry , symptomatic congestive heart failure ( New York Heart Association &gt; class II ) , unstable angina pectoris , unstable cardiac arrhythmia require medication . Evidence preexist uncontrolled hypertension . Patients whose hypertension control antihypertensive therapy eligible . Patients know Hepatitis B C human immunodeficiency virus ( HIV ) infection Evidence medical condition ( psychiatric illness , infectious disease , physical examination laboratory finding ) opinion investigator may interfere plan treatment , affect patient compliance place patient high risk treatmentrelated complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>